Working… Menu
Trial record 2 of 2 for:    BIBF | Lung Cancer | Italy

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01346540
Recruitment Status : Completed
First Posted : May 3, 2011
Results First Posted : September 10, 2018
Last Update Posted : September 10, 2018
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

The LUME-Lung3 study is in 2 parts:

Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and cisplatin.

Phase II - Placebo controlled efficacy study of BIBF 1120 added to standard 3 weekly cycles of gemcitabine and cisplatin therapy in patients with at least Stable Disease after 2 previous courses of the chemotherapy

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: BIBF 1120 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: LUME-Lung 3: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology
Actual Study Start Date : April 14, 2011
Actual Primary Completion Date : April 25, 2013
Actual Study Completion Date : January 17, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: BIBF 1120
VEGF inhibitor
Drug: BIBF 1120
VEGF inhibitor

Placebo Comparator: Placebo
BIBF 1120 placebo
Drug: Placebo
BIBF 1120 placebo

Primary Outcome Measures :
  1. Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle for the Determination of the Maximum Tolerated Dose (MTD) [ Time Frame: Up to 21 days from first drug administration ]
    The following drug-related adverse events (AEs) qualified as a DLT: Non-hematological toxicity - Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥3 events excluding transient electrolyte abnormality, hyperuricemia and isolated elevation of gamma-glutamyl trans-peptidase. Gastrointestinal AEs (nausea, vomiting, diarrhoea, abdominal pain) or hypertension of CTCAE Grade ≥3 despite optimal supportive care/intervention. Alanine aminotransferase and or Aspartate aminotransferase elevation of CTCAE Grade ≥3. Haematological toxicity - Uncomplicated CTCAE Grade 4 neutropenia (that was not associated with fever of ≥38.5° Celsius) for >7 days (except during Cycle 1). CTCAE Grade 4 febrile neutropenia associated with fever ≥38.5º Celsius. A decrease in platelet levels to CTCAE Grade 4 or CTCAE Grade 3 associated with bleeding or requiring transfusion. The inability to resume nintedanib dosing within 14 days of stopping due to a drug-related AE was also considered a DLT.

  2. Maximum Tolerated Dose (MTD) of Nintedanib Added to Cisplatin/Gemcitabine Based on the Occurrence of DLTs During Treatment Cycle 1. [ Time Frame: Up to 21 days from first drug administration ]
    The MTD was defined as the dose of nintedanib administered with gemcitabine/cisplatin at which no more than 1 of 6 patients experienced DLT (or one dose tier below that dose at which 2 or more of 6 patients experienced DLT) during the first 21-day treatment cycle. Any DLTs experienced after the start of the second treatment period were considered separately.

Secondary Outcome Measures :
  1. Incidence of Adverse Events (AEs) According to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00 [ Time Frame: From the first drug administration until 28 days after last study drug administration, up to 804 days ]
    Incidence of adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00 with grade 1-5.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

Run-in Phase I

  1. Histologically or cytologically confirmed diagnosis of stage IIIB/IV or recurrent Non Small Cell Lung Cancer (NSCLC) with squamous cell histology.
  2. Measurable disease according to Response Evaluation Criteria in Solid Tumours ( RECIST 1.1).
  3. Patient Eastern Cooperative Oncology Group (ECOG) score of 0-1.
  4. Male or female patients age = 18 years.
  5. Life expectancy of at least three (3) months.
  6. Written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines.

    Phase II - in addition to the above criteria:

  7. Radiologically-confirmed at least stable disease after 2 prior cycles of cisplatin / gemcitabine chemotherapy.

Exclusion criteria:

  1. Prior therapy for advanced or metastatic or recurrent Non Small Cell Lung Cancer (NSCLC). One prior adjuvant, neoadjuvant or adjuvant + neoadjuvant treatment is allowed if at least 12 months have elapsed between the end of the treatment and randomization
  2. Prior treatment with other Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors (other than bevacizumab)
  3. Any contraindications for treatment with gemcitabine and/or cisplatin.
  4. Use of any investigational drug within 4 weeks of entering the 1199.82 study.
  5. History of major thrombotic or clinically relevant bleeding event in the past 6 months.
  6. Significant cardiovascular diseases (i.e. hypertension not controlled by medication.
  7. Surgery within 4 weeks (except tumour biopsy) prior randomisation and incomplete wound healing.
  8. Active brain metastases
  9. Radiotherapy (except extremities) within 3 months prior to baseline imaging and radiotherapy for brain metastasis < 4 weeks prior baseline imaging.
  10. Any other current malignancy or malignancy diagnosed within the past five (5) years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01346540

Layout table for location information
1199.82.39004 Boehringer Ingelheim Investigational Site
Milano, Italy
1199.82.3102 Boehringer Ingelheim Investigational Site
Maastricht, Netherlands
1199.82.3401 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1199.82.3406 Boehringer Ingelheim Investigational Site
Madrid, Spain
1199.82.3410 Boehringer Ingelheim Investigational Site
Málaga, Spain
United Kingdom
1199.82.4401 Boehringer Ingelheim Investigational Site
London, United Kingdom
1199.82.4402 Boehringer Ingelheim Investigational Site
Manchester, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT01346540    
Other Study ID Numbers: 1199.82
2010-019707-32 ( EudraCT Number: EudraCT )
First Posted: May 3, 2011    Key Record Dates
Results First Posted: September 10, 2018
Last Update Posted: September 10, 2018
Last Verified: August 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Carcinoma, Bronchogenic
Respiratory Tract Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action